Emerging Epigenetic Therapies for Brain Tumors.

Neuromolecular Med

Department of Neurosurgery, Mulva Clinic for the Neurosciences and LIVESTRONG Cancer Institutes and Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA.

Published: March 2022

Malignant brain tumors are among the most intractable cancers, including malignancies such as glioblastoma, diffuse midline glioma, medulloblastoma, and ependymoma. Unfortunately, treatment options for these brain tumors have been inadequate and complex, leading to poor prognoses and creating a need for new treatment modalities. Aberrant epigenetics define these types of tumors, with underlying changes in DNA methylation, histone modifications, chromatin structure and noncoding RNAs. Epigenetic-targeted therapies are an alternative that have the potential to reverse the epigenetic deregulation underpinning brain malignancies. Various drugs targeting epigenetic regulators have shown promise in preclinical and clinical testing. In this review, we highlight some of the recent emerging epigenetic targeted therapies for brain tumors being evaluated in the discovery phase and in clinical trials.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12017-021-08691-xDOI Listing

Publication Analysis

Top Keywords

brain tumors
16
emerging epigenetic
8
therapies brain
8
brain
5
tumors
5
epigenetic therapies
4
tumors malignant
4
malignant brain
4
tumors intractable
4
intractable cancers
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!